T1	AdverseReaction 54 83	Nephrogenic Systemic Fibrosis
T3	AdverseReaction 255 268;282 291	Anaphylactoid reactions
T4	AdverseReaction 269 281;282 291	anaphylactic reactions
T5	AdverseReaction 297 311;338 352	cardiovascular manifestations
T6	AdverseReaction 313 324;338 352	respiratory manifestations
T7	AdverseReaction 328 352	cutaneous manifestations
T8	Severity 367 371	mild
T9	Severity 375 381	severe
T10	AdverseReaction 624 653	nephrogenic systemic fibrosis
T11	AdverseReaction 655 658	NSF
T12	DrugClass 561 593	Gadolinium-based contrast agents
T14	AdverseReaction 883 886	NSF
T15	DrugClass 867 871	GBCA
T16	AdverseReaction 1240 1243	NSF
T17	Factor 1244 1247	may
T18	AdverseReaction 1258 1263	fatal
T19	AdverseReaction 1280 1288	fibrosis
T26	AdverseReaction 2877 2889;2908 2917	Anaphylactic reactions
T27	AdverseReaction 2894 2917	anaphylactoid reactions
T28	Factor 3407 3410	may
T29	AdverseReaction 3440 3465	hypersensitivity reaction
T30	AdverseReaction 3888 3907	acute kidney injury
T31	DrugClass 3956 3961	GBCAs
T32	AdverseReaction 4465 4479;4494 4511	administration tissue irritation
T33	Factor 4480 4483	may
T2	AdverseReaction 393 398	death
T20	AdverseReaction 3049 3069	circulatory collapse
T21	AdverseReaction 3074 3078	died
T22	AdverseReaction 237 253	Hypersensitivity
T23	Severity 1267 1279	debilitating
E1	AdverseReaction:T1
E3	AdverseReaction:T3
E4	AdverseReaction:T4
E5	AdverseReaction:T5 Effect:E8 Effect2:E9
E6	AdverseReaction:T6 Effect:E8 Effect2:E9
E7	AdverseReaction:T7 Effect:E8 Effect2:E9
E8	Severity:T8
E9	Severity:T9
E10	AdverseReaction:T10 Hypothetical2:E12
E11	AdverseReaction:T11 Hypothetical:E12
E12	DrugClass:T12
E14	AdverseReaction:T14 Hypothetical:E15
E15	DrugClass:T15
E16	AdverseReaction:T16 Hypothetical:E17
E17	Factor:T17
E18	AdverseReaction:T18 Hypothetical:E17
E19	AdverseReaction:T19 Hypothetical:E17 Effect:E23
E26	AdverseReaction:T26
E27	AdverseReaction:T27
E28	Factor:T28
E29	AdverseReaction:T29 Hypothetical:E28
E30	AdverseReaction:T30 Hypothetical:E31
E31	DrugClass:T31
E32	AdverseReaction:T32 Hypothetical:E33
E33	Factor:T33
E2	AdverseReaction:T2
E20	AdverseReaction:T20
E21	AdverseReaction:T21
E22	AdverseReaction:T22
E23	Severity:T23
A1	CUI E1 C3888044
A2	UMLS-Preferred-Name E1 Nephrogenic Systemic Fibrosis
A3	MEDDRA-PT E1 Nephrogenic systemic fibrosis
A4	MEDDRA-PT-ID E1 10067467
A5	CUI E3 C0340865
A6	UMLS-Preferred-Name E3 Anaphylactoid reaction
A7	MEDDRA-PT E3 Anaphylactoid reaction
A8	MEDDRA-PT-ID E3 10002216
A9	CUI E4 C0002792
A10	UMLS-Preferred-Name E4 anaphylaxis
A11	MEDDRA-PT E4 Anaphylactic reaction
A12	MEDDRA-PT-ID E4 10002198
A13	CUI E5 C0476270
A14	UMLS-Preferred-Name E5 Cardiovascular symptoms
A15	MEDDRA-PT E5 Cardiovascular symptom
A16	MEDDRA-PT-ID E5 10075534
A17	CUI E6 C0037090
A18	UMLS-Preferred-Name E6 Signs and Symptoms, Respiratory
A19	MEDDRA-PT E6 Respiratory symptom
A20	MEDDRA-PT-ID E6 10075535
A21	CUI E7 C0037285
A22	UMLS-Preferred-Name E7 Skin Manifestations
A23	MEDDRA-PT E7 Cutaneous symptom
A24	MEDDRA-PT-ID E7 10075531
A25	CUI E10 C3888044
A26	UMLS-Preferred-Name E10 Nephrogenic Systemic Fibrosis
A27	MEDDRA-PT E10 Nephrogenic systemic fibrosis
A28	MEDDRA-PT-ID E10 10067467
A29	CUI E11 C3888044
A30	UMLS-Preferred-Name E11 Nephrogenic Systemic Fibrosis
A31	MEDDRA-PT E11 Nephrogenic systemic fibrosis
A32	MEDDRA-PT-ID E11 10067467
A33	CUI E14 C3888044
A34	UMLS-Preferred-Name E14 Nephrogenic Systemic Fibrosis
A35	MEDDRA-PT E14 Nephrogenic systemic fibrosis
A36	MEDDRA-PT-ID E14 10067467
A37	CUI E16 C3888044
A38	UMLS-Preferred-Name E16 Nephrogenic Systemic Fibrosis
A39	MEDDRA-PT E16 Nephrogenic systemic fibrosis
A40	MEDDRA-PT-ID E16 10067467
A41	CUI E18 C1306577
A42	UMLS-Preferred-Name E18 Death (finding)
A43	MEDDRA-PT E18 Death
A44	MEDDRA-PT-ID E18 10011906
A45	CUI E19 C0016059
A46	UMLS-Preferred-Name E19 Fibrosis
A47	MEDDRA-PT E19 Fibrosis
A48	MEDDRA-PT-ID E19 10016642
A49	CUI E26 C0002792
A50	UMLS-Preferred-Name E26 anaphylaxis
A51	MEDDRA-PT E26 Anaphylactic reaction
A52	MEDDRA-PT-ID E26 10002198
A53	CUI E27 C0340865
A54	UMLS-Preferred-Name E27 Anaphylactoid reaction
A55	MEDDRA-PT E27 Anaphylactoid reaction
A56	MEDDRA-PT-ID E27 10002216
A57	CUI E29 C0020517
A58	UMLS-Preferred-Name E29 Hypersensitivity
A59	MEDDRA-PT E29 Hypersensitivity
A60	MEDDRA-PT-ID E29 10020751
A61	LLT E29 Hypersensitivity reaction
A62	LLT-ID E29 10020756
A63	CUI E30 C2609414
A64	UMLS-Preferred-Name E30 Acute kidney injury
A65	MEDDRA-PT E30 Acute kidney injury
A66	MEDDRA-PT-ID E30 10069339
A67	CUI E32 C3888600
A68	UMLS-Preferred-Name E32 Administration site irritation
A69	MEDDRA-PT E32 Administration site irritation
A70	MEDDRA-PT-ID E32 10075941
A71	CUI E2 C1306577
A72	UMLS-Preferred-Name E2 Death (finding)
A73	MEDDRA-PT E2 Death
A74	MEDDRA-PT-ID E2 10011906
A75	CUI E20 C0036974
A76	UMLS-Preferred-Name E20 Shock
A77	MEDDRA-PT E20 Circulatory collapse
A78	MEDDRA-PT-ID E20 10009192
A79	CUI E21 C1306577
A80	UMLS-Preferred-Name E21 Death (finding)
A81	MEDDRA-PT E21 Death
A82	MEDDRA-PT-ID E21 10011906
A83	CUI E22 C0020517
A84	UMLS-Preferred-Name E22 Hypersensitivity
A85	MEDDRA-PT E22 Hypersensitivity
A86	MEDDRA-PT-ID E22 10020751
